Moderna (MRNA) Touches 52-Week High on Strong Clinical Results

We recently published 10 Big Names Leaving Wall Street Behind; 7 Are Hitting Record Highs. Moderna Inc. (NASDAQ:MRNA) was one of the worst performers on Wednesday.

Moderna surged to a new 52-week high of $50 on Wednesday, a 16 percent jump, as investors took heart from the strong results of its clinical study for Intismeran Autogene in Combination With KEYTRUDA(R) in patients with high-risk melanoma.

At market close, the stock pared gains to end the session just up by 15.84 percent at $49.81 apiece.

In an updated report, Moderna Inc. (NASDAQ:MRNA) said that the median five-year follow-up data from the Phase 2b study showed that the therapy reduced death risks of patients by 49 percent as compared to Keytruda alone.

Moderna Inc. (NASDAQ:MRNA) and Merck plan to present further data from follow up analyses of primary and secondary endpoints at an upcoming medical meeting.

In collaboration with Merck, the Phase 3 clinical trial for adjuvant melanoma (INTerpath-001, NCT05933577) is fully enrolled.

Two non-small cell lung cancer (NSCLC) Phase 3 studies—evaluating adjuvant treatment in patients with completely resected NSCLC and adjuvant treatment for patients with resectable NSCLC after receiving neoadjuvant KEYTRUDA plus platinum-based chemotherapy—are enrolling.

“The randomized Phase 2 study for adjuvant renal cell carcinoma is fully enrolled. Randomized Phase 2 studies for patients with resected muscle invasive and resected non-muscle invasive bladder cancer are enrolling, a Phase 2 study of first-line treatment for patients with metastatic melanoma and a Phase 2 study of first-line treatment for patients with metastatic squamous NSCLC are also enrolling,” Moderna Inc. (NASDAQ:MRNA) said.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.